Q4 2025 Strides Pharma Science Ltd Earnings Call Transcript

May 22, 2025 / 10:30 AM GMT

Release Date Price: ₹730.35 (+5.00%)

Transcript

Key Points

Positve

Strides Pharma Science Ltd (BOM:532531) reported a significant revenue growth of 17.2%, surpassing their target range of 12-15%.
The company achieved its highest ever operational EPS at ₹37.46 per share, reflecting a strong year-on-year growth.
Strides Pharma Science Ltd (BOM:532531) successfully launched 7 new products in the US market and maintained market-leading positions in 36 out of 73 products.
The company reported a substantial reduction in net debt by ₹530 crore during the year, improving its financial leverage.
Gross margins were maintained at a healthy range of 58-59% for the second consecutive quarter post-demerger.

Negative

The company's other regulated markets have shown flat revenue growth over the last four quarters, indicating potential challenges in these regions.
Despite significant debt reduction, the company still holds a net debt of ₹1,500 crore, which may pose financial risks.
The cost of funds remains relatively high at approximately 9%, which could impact profitability if not reduced.
There is uncertainty regarding the impact of US tariffs on the company's operations, which could affect future growth.
The company faces challenges in expanding its product portfolio and acquiring new customers in the UK and Nordic markets.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SRID.NS - Strides Pharma Science Ltd
Q4 2025 Strides Pharma Science Ltd Earnings Call
May 22, 2025 / 10:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, good day and welcome to the Q4 and F 525 earnings conference call. Stris Pharma Science Limited. As a reminder, all participant signs will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing, then 0 on your touchtone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Abhishek Singer.

Thank you and over to you, sir.

--------------------------------------------------------------------------------
Unidentified_2 [2]
----------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.